Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Dietary nitrate in the form of beet juice reduces restenosis after percutaneous intervention in a randomized trial.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
Recently released national data on drug use and abuse among Americans.
2.
Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients
3.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
4.
Scholastic performance is a key concern for young cancer patients, study finds
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
2.
Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology
3.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
4.
A Review of Cancer Treatment Evolution Towards Stem Cells and Gene Therapy
5.
Clinical Analysis of Prostate Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge